Lixisenatide (Adlyxin / Lyxumia): short-acting GLP-1 receptor agonist research overview

Lixisenatide is a short-acting, once-daily GLP-1 receptor agonist that was marketed as Adlyxin in the United States and Lyxumia in Europe and other markets. Approved by the FDA in July 2016 for the treatment of type 2 diabetes in adults as an adjunct to diet and exercise, lixisenatide was voluntarily discontinued in the US market by its manufacturer Sanofi in January 2023 for commercial reasons — not for safety or efficacy concerns. It remains available in some international markets. Lixisenatide is distinguished from longer-acting GLP-1 agonists by its pronounced postprandial glucose-lowering effect driven by gastric emptying delay, and it has a cardiovascular safety profile documented in the ELIXA outcomes trial (Pfeffer et al., NEJM 2015, PMID 26630143).

What is lixisenatide?

Lixisenatide is a synthetic 44-amino acid peptide GLP-1 receptor agonist based on the exendin-4 scaffold, modified at the C-terminus with six additional lysine residues. Like efpeglenatide and exenatide, it uses the exendin-4 backbone (approximately 50% sequence homology with native human GLP-1) rather than a GLP-1 analog sequence. The C-terminal polybasic tail contributes to its pharmacokinetic profile but, unlike semaglutide or liraglutide, lixisenatide does not employ fatty-acid acylation — its elimination half-life is approximately 3 hours, necessitating once-daily dosing (rather than weekly) and resulting in a pharmacodynamic profile dominated by effects on postprandial rather than fasting glucose.

The FDA approved lixisenatide as Adlyxin on July 28, 2016 (NDA 208471), making it the sixth GLP-1 receptor agonist to receive US approval. Sanofi marketed it in combination with insulin glargine as iGlarLixi (Soliqua 100/33 in the US, Suliqua in EU). In October 2022, Sanofi announced that Adlyxin would be discontinued in the US effective January 1, 2023, citing portfolio strategy and the availability of alternative treatments; Sanofi did not cite any safety issues. Lyxumia remains available in select markets outside the US. The iGlarLixi combination product (Soliqua) remained available in the US independently.

Mechanism of action

Lixisenatide is a full agonist at the GLP-1 receptor. Its mechanism is substantially shared with the broader GLP-1 agonist class: glucose-dependent stimulation of insulin secretion in pancreatic beta cells, suppression of glucagon secretion during hyperglycemia, slowing of gastric emptying, and activation of central appetite-suppression circuits in the hypothalamus and brainstem. Its short half-life, however, means these effects are concentrated in the postprandial window following each dose administration. The gastric emptying delay effect — which is the primary mechanism reducing postprandial glucose excursions — is particularly pronounced for short-acting GLP-1 agonists like lixisenatide and exenatide compared to the longer-acting class members.

The exendin-4 backbone provides inherent DPP-4 resistance at the N-terminus (unlike native GLP-1, which is rapidly cleaved at the Ala-Glu bond at position 2 by DPP-4). However, lixisenatide still has a short half-life due to renal clearance rather than enzymatic degradation being the dominant elimination pathway. This distinguishes it from longer-acting agents that have extended half-lives through albumin binding (semaglutide, liraglutide) or Fc-fusion (efpeglenatide, dulaglutide).

What the research shows

The ELIXA trial (Evaluation of Lixisenatide in Acute Coronary Syndrome) was the pivotal cardiovascular outcomes trial for lixisenatide, published by Pfeffer et al. in the New England Journal of Medicine in November 2015 (PMID 26630143). ELIXA was a multicenter, randomized, double-blind, placebo-controlled trial enrolling 6,068 patients with type 2 diabetes and a recent acute coronary syndrome event (within 180 days). Participants were randomized to lixisenatide 10–20 mcg once daily or placebo in addition to standard care, with a median follow-up of 25 months.

The primary composite endpoint — cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for unstable angina (4P-MACE plus unstable angina) — occurred in 13.4% of lixisenatide patients versus 13.2% of placebo patients (HR 1.02; 95% CI 0.89–1.17; P<0.001 for non-inferiority; P=0.81 for superiority) [1]. ELIXA thus demonstrated cardiovascular safety (non-inferiority) but not a cardiovascular benefit. This outcome differentiated lixisenatide from the longer-acting GLP-1 agonists liraglutide (LEADER) and semaglutide (SUSTAIN-6), which demonstrated cardiovascular superiority — and from efpeglenatide (AMPLITUDE-O), which also demonstrated superiority.

A pharmacological explanation for the neutral ELIXA result relative to positive CVOTs of longer-acting agents has been proposed: the sustained versus pulsatile GLP-1R activation hypothesis suggests that continuous receptor exposure (as with long-acting agents) may be required for the cardiovascular pleiotropic effects, whereas intermittent exposure with short-acting agents may not provide sufficient receptor engagement in cardiac and vascular tissues to replicate those benefits. This hypothesis is consistent with the observation that all positive GLP-1 CVOTs (LEADER, SUSTAIN-6, AMPLITUDE-O, REWIND for dulaglutide) involved long-acting or once-weekly agents.

In phase 3 glycemic trials, lixisenatide 20 mcg once daily reduced HbA1c by approximately 0.9–1.1% from baseline versus placebo-adjusted reductions, with the primary benefit on postprandial glucose. Weight loss of approximately 2–3 kg was observed versus placebo, smaller than that seen with longer-acting GLP-1 agonists, consistent with its shorter duration of action and lesser effect on fasting glucose and appetite suppression.

Pharmacokinetics

Lixisenatide has a plasma half-life of approximately 3 hours. It is administered subcutaneously once daily, within 60 minutes before the main meal of the day. Peak plasma concentrations are achieved within 1–3.5 hours of subcutaneous injection. Unlike acylated peptide GLP-1 agonists, lixisenatide does not employ albumin binding for extended circulation; its half-life reflects direct renal and proteolytic clearance. Steady-state is achieved rapidly, within the first few days of once-daily dosing. The FDA-approved label (NDA 208471) remains the definitive pharmacokinetic reference for clinical parameters, noting that renal impairment reduces clearance and may require dose adjustment in severe cases.

Lixisenatide is not metabolized by CYP450 enzymes. As a peptide, it undergoes proteolytic degradation and renal filtration. Drug–drug interactions related to its profound gastric emptying delay effect are clinically relevant: orally administered drugs with narrow therapeutic indices that depend on consistent GI absorption (e.g., levothyroxine, warfarin, oral contraceptives) should be taken with care, and timing relative to lixisenatide administration matters. The approved Adlyxin label (which remains available from FDA DailyMed despite product discontinuation) provides full interaction guidance.

Dose ranges from research and approved labeling

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

The FDA-approved Adlyxin dosing regimen (from NDA 208471) was: initiate at 10 mcg subcutaneously once daily for 14 days, then titrate to the maintenance dose of 20 mcg once daily. Lixisenatide was injected within 60 minutes before the main meal of the day. The starting pen device delivered 10 mcg per injection; the maintenance pen delivered 20 mcg per injection. In ELIXA, participants were dose-escalated from 10 mcg to 20 mcg over a 2-week period, with a 2-week single-blind run-in on placebo. Because Adlyxin has been discontinued in the US and the drug is not available for new prescriptions domestically, these doses are presented for historical and research reference only.

Storage and handling

Per the Adlyxin FDA label (NDA 208471, last updated 2016): store new (unused) pens in the refrigerator at 36–46 °F (2–8 °C); do not freeze. After first use, the pen may be stored at room temperature up to 77 °F (25 °C) and should be discarded after 14 days. Protect from light. Research-grade lixisenatide peptide should be stored as lyophilized powder at −20 °C; reconstituted solutions at 2–8 °C and used within the period specified by the supplier's certificate of analysis.

What lixisenatide is NOT

Lixisenatide is not semaglutide or liraglutide. Those are longer-acting, fatty-acid-acylated GLP-1 analogs with weekly (semaglutide) or daily (liraglutide) dosing and demonstrated cardiovascular superiority in their CVOTs. Lixisenatide's once-daily short-acting profile places it in a different pharmacodynamic category, with greater postprandial specificity and a neutral CVOT result. Lixisenatide is not exenatide; although both use the exendin-4 backbone, they are distinct peptides with different C-terminal modifications. Exenatide (Byetta) requires twice-daily dosing; lixisenatide requires once-daily dosing. Exenatide has its own CVOT (EXSCEL), which also showed cardiovascular neutrality, consistent with the short-acting class pattern.

Lixisenatide is not available as Adlyxin in the US as of January 2023. It was not withdrawn for safety reasons — the FDA did not mandate discontinuation. It is not listed on the FDA drug shortage database as a shortage; it was a voluntary commercial discontinuation. The FDA label for Adlyxin remains accessible via DailyMed and represents valid reference documentation for historical, pharmacological, and research purposes.

Frequently asked questions

Why was lixisenatide discontinued in the US?

Sanofi discontinued Adlyxin (lixisenatide) in the US effective January 2023 for commercial reasons — specifically, strategic portfolio decisions and competition from longer-acting GLP-1 agonists. There were no safety or efficacy concerns driving the discontinuation. Lyxumia remains available in some international markets.

What did ELIXA show?

ELIXA (Pfeffer et al., NEJM 2015, PMID 26630143) demonstrated that lixisenatide was non-inferior to placebo for MACE in adults with type 2 diabetes post-ACS — confirming cardiovascular safety but not superiority. The result was neutral: no cardiovascular benefit, no cardiovascular harm.

Is lixisenatide still available anywhere?

Yes. Lyxumia (lixisenatide) remains approved and marketed in the European Union and other international markets as of 2025–2026. Adlyxin is no longer available for new dispensing in the United States.

How does lixisenatide compare to longer-acting GLP-1 agonists?

Lixisenatide is primarily a postprandial glucose agent due to its short half-life and pronounced gastric emptying delay. Longer-acting agents (semaglutide, liraglutide, dulaglutide) have more consistent fasting glucose effects, greater weight loss, and demonstrated cardiovascular superiority in CVOTs. Lixisenatide's neutral CVOT is consistent with the short-acting exendin-4 class.

What is iGlarLixi?

iGlarLixi (Soliqua 100/33 in the US; Suliqua in EU) is a fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide 33 mcg/mL in a single injection pen, developed by Sanofi. Soliqua remained commercially available in the US after Adlyxin's discontinuation because it is a separate product. The combination product allows the insulin glargine to address fasting glucose while lixisenatide addresses postprandial glucose excursions.

References

1. Pfeffer MA, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (ELIXA). N Engl J Med. 2015;373(23):2247–2257. PMID 26630143. https://pubmed.ncbi.nlm.nih.gov/26630143/

2. FDA label: Adlyxin (lixisenatide) injection, NDA 208471. Approved July 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471orig1s000lbl.pdf

3. DailyMed: Adlyxin (lixisenatide) prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=lixisenatide

4. RxLess: Adlyxin (lixisenatide) discontinuation notice. https://www.rxless.com/resources/adlyxin-lixisenatide-will-no-longer-be-available-in-the-us

5. AAFP clinical review: Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus. Am Fam Physician. 2017;96(4):257–258. https://www.aafp.org/pubs/afp/issues/2017/0815/p257.html